News

Relation Therapeutics, a drug development company driven by data science and machine learning (ML), today announces Project RE, which will apply Relation Therapeutics’ and its partners’ technology to the identification of repurposed drug combinations as potential therapeutic candidates for COVID-19.…...

(1) Juvenescence’s Greg Bailey on transformative scientific opportunities, immuno-resilience, modifying aging and funding. Continuing our series of interviews with our Advisory Panel members, we spoke to Greg Bailey, CEO of biopharmaceutical company Juvenescence, who brought us up-to-speed on the company’s fundraise and his very…...

LyGenesis’ Michael Hufford talks Longevity research programmes and investment with LongevityTechnology. Kicking off a series of interviews with our Advisory Panel members, we chatted to Michael Hufford, PhD, the CEO of LyGenesis, an organic regeneration company enabling a patient’s own lymph nodes to…...

Greg Bailey, the CEO of Juvenescence, discusses Juvenescence and some of the innovations within the longevity space. Interview with 'The Simple BioTech Podcast'. 'The Simple BioTech Podcast' found here....

Allows industry and academia access to cGMP-grade, NIH-registered AgeX ESI human pluripotent stem cells for development of cellular therapeuticsAgeX ESI cell lines are among only a few pluripotent stem cell lines from which derived cell therapy candidates have been granted…...

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team. Ellen joins the Juvenescence team as the CEO of the Epigenetics…...

Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDSImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in…...

Juvenescence Limited, a life sciences company focused on therapies to modify aging and increasing healthy human longevity, and G3 Therapeutics, a trailblazer biotechnology company leveraging biological big data for drug discovery and development, today announced the formation of Juvenomics Limited,…...

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeX’s UniverCyteTM gene technology to…...

Dr. Greg Bailey interview with Longevity.Technology: Juvenescence looks to bring on board a completely new mechanism for regeneration;Q3 product launch of a direct-to-consumer ketone ester drink product that is geroprotective, neuroprotective and cardioprotective;Reversing liver failure for people who would otherwise…...

 AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from…...

Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform.Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions.Builds on University’s research in neural stem cell transplantation for Huntington’s disease, including safety and…...